The Latest Cardiac and Vascular News
Company Expands Global Reach with Latest Endovascular Aneurysm Repair (EVAR) Technology IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a leader in the treatment of vascular disease, today announced the first implant of its ALTO® Abdominal Stent Graft in Canada following recent approval from […]
Company Expands Vascular Reach to Treat Unmet Needs of Both AAA and PAD Patients IRVINE, Calif.—(BUSINESS WIRE)—April 13, 2021—Endologix LLC, a leader in the treatment of vascular disease, today announced it has completed the acquisition of PQ Bypass, Inc., a privately […]
First European Commercial Case Completed at East & North Hertfordshire Hospital in England IRVINE, Calif.–(BUSINESS WIRE)—Oct 15, 2020–Furthering its mission to transform the treatment of aortic disorders, Endologix LLC today announced the first implant of its ALTO™ Abdominal Stent Graft, […]
IRVINE, Calif.–(BUSINESS WIRE)–Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc. (OTC: ELGXQ) (“Endologix” or the “Company”) today announced the first implant of its recently approved ALTO® endograft outside of the United States, completed by Andrew Holden, MD, […]
IRVINE, Calif.–(BUSINESS WIRE)–Transforming the treatment of aortic disorders, Endologix® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced that it has received a CE Mark for the ALTO™ Abdominal Stent Graft System (ALTO). “We are very excited to receive a CE […]
IRVINE, Calif.–(BUSINESS WIRE)–Transforming the treatment of aortic disorders, Endologix® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced the first commercial implant and the U.S. commercial release of its recently FDA-approved ALTO® endograft for the treatment of abdominal aortic aneurysms (AAA). “ALTO […]
Commences voluntary Chapter 11 process with access to $30.8 million in DIP financing Files consensual plan of reorganization that would reduce approximately $180 million in debt and provide an approximately $30 million in additional exit financing Confirms launch of Alto […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer (CFO), will be departing the Company effective July 1, 2020 to become […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root cause of polymer […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Tim A. Benner to succeed John Zehren as the Company’s Chief Commercial Officer, effective […]
